読み込み中
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
前日終値
$1.73
−$0.02 · -1.14%
日中の時刻はETです。市場データは遅延する場合があります。
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
日中レンジ
現在 $1.73
52週レンジ
現在 $1.73
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
26
割高
センチメント
40
弱気
リスク
66
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
日中レンジ
現在 $1.73
52週レンジ
現在 $1.73
営業利益
純利益
| 指標（CAD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | 8.37万 CAD | 14.5万 CAD | 11.41万 CAD | 4.3万 CAD |
| 粗利益 | — | −8.37万 CAD | −14.5万 CAD | −11.41万 CAD | −4.3万 CAD |
| 研究開発 | 1390.72万 CAD | 1565.94万 CAD | 800.06万 CAD | 1642.58万 CAD | 688.29万 CAD |
| 販売・一般管理 | 1117.2万 CAD | 917.22万 CAD | 963.26万 CAD | 628.27万 CAD | 598.28万 CAD |
| 営業費用 | 2507.93万 CAD | 2483.15万 CAD | 1763.32万 CAD | 2270.84万 CAD | 1286.57万 CAD |
| 受取利息 | 33.34万 CAD | 81.21万 CAD | 55.01万 CAD | 19.96万 CAD | 2.96万 CAD |
| 支払利息 | — | — | — | 51.01万 CAD | — |
| 減価償却費と償却費 | 5.58万 CAD | 8.37万 CAD | 14.5万 CAD | 11.41万 CAD | 4.3万 CAD |
| 営業利益 | −2507.93万 CAD | −2491.53万 CAD | −1777.82万 CAD | −2282.25万 CAD | −1290.87万 CAD |
| 純利益 | −4411.73万 CAD | −2398.98万 CAD | −2238.4万 CAD | −2054万 CAD | −1282.34万 CAD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$12.00
上昇余地（593.64%）価格履歴は利用できません
最高：$12.00平均：$12.00最低：$12.00この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
